[The treatment of solid tumors with monoclonal antibodies].
Patients with B-cell lymphomas, gastrointestinal tumors and melanomas were treated in pilot and phase-I clinical studies with monoclonal antibodies directed to tumor-associated antigens in recent years. Side effects of this new treatment approach were minor. Tumor regressions were observed in all three groups of tumors.